Updated on 27 October 2026
Microbial Biologics Expertise for Recombinant Protein Development, Purification and Scale-up
Administration Lead at Paras Biopharmaceuticals Finland Oy
Oulu, Finland
About
Paras Biopharmaceuticals Finland Oy offers specialised technical expertise in microbial recombinant protein development for Horizon Europe Health projects. We seek opportunities to contribute as a technical partner in research consortia and to support funded projects through subcontracted protein development and process optimisation.
Our strengths include E. coli and yeast expression systems, particularly for non-glycosylated and difficult-to-express proteins. Our expertise covers nanobodies, diabodies, domain antibodies, scFv fusion proteins, Fc-fusions, interleukins and long peptides.
We can contribute to defined technical work packages or subcontracted tasks involving expression and fermentation development, protein folding and refolding, solubility and aggregation control, downstream processing, purification, analytical characterisation, troubleshooting and fermentation scale-up at 20 L, 150 L and 750 L.
We are interested in projects developing therapeutic proteins, antibody-based biologics and other relevant recombinant protein products where microbial production offers a suitable approach. We welcome contact from Horizon Europe coordinators preparing proposals, research organisations and biotechnology companies seeking a technical partner or external support for specific protein development, purification or scale-up activities.
If your planned or ongoing project requires these capabilities, we would be happy to discuss where Paras could contribute.
Website: https://www.parasbiopharma.com/microbial-biologics-cdmo.php
Topic
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
Type
- Partner seeks Consortium/Coordinator
Attached files
Organisation
Similar opportunities
Project cooperation
Microbial Biologics Expertise for Recombinant Protein Development, Purification and Scale-up
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Mark Jackson
Administration Lead at Paras Biopharmaceuticals Finland Oy
Oulu, Finland
Project cooperation
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Mark Jackson
Administration Lead at Paras Biopharmaceuticals Finland Oy
Oulu, Finland
Project cooperation
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Mark Jackson
Administration Lead at Paras Biopharmaceuticals Finland Oy
Oulu, Finland